,
,
,
, Chirurgie
, Critère principal : survie sans progression
,
,
,
,
,
, Comparaison du GETUG13 à notre étude
, Autres stratégies thérapeutiques adaptées à la décroissance des marqueurs tumoraux?????
,
,
,
,
,
Chemotherapy in adult germ cell tumors, C Rev Oncol Hematol, vol.22, pp.229-263, 1996. ,
Testicular germ-cell cancer, N Engl J Med, vol.337, pp.242-253, 1997. ,
5-The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy, J Clin Oncol, vol.24, pp.4906-4911, 1997. ,
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide, N Engl J Med, vol.316, pp.1435-1440, 1987. ,
A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors, J Clin Oncol, vol.6, pp.1031-1040, 1988. ,
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol, J Clin Oncol, vol.9, pp.1163-1172, 1991. ,
Failure of high-dose cyclophosphamide and etoposide combined with doubledose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial, Eur Urol, vol.51, pp.739-746, 2007. ,
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors, J Clin Oncol, vol.25, pp.247-256, 2007. ,
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poorprognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974), Ann Oncol, vol.22, pp.1054-1061, 2011. ,
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study, J Clin Oncol, vol.16, pp.1287-1293, 1998. ,
Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor, Anticancer Drugs, vol.7, issue.6, pp.716-724, 1996. ,
A phase II trial of paclitaxel in refractory germ cell tumors, Cancer, vol.82, issue.7, pp.1381-1387, 1998. ,
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours, Cancer Chemother Pharmacol, vol.44, issue.4, pp.349-53, 1999. ,
Management of intermediateprognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP, Int J Cancer, vol.83, issue.6, pp.831-834, 1999. ,
Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors, Urol. Oncol, vol.5, issue.4, pp.134-138, 2000. ,
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer, J Clin Oncol, vol.17, issue.2, pp.509-520, 1999. ,
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients, J Cancer Res Clin Oncol, vol.125, issue.12, pp.707-718, 1999. ,
Oxaliplatin in patients (pts) with cisplatin-refractory germ-cell cancer (GCT), Proc Am Soc Clin Oncol, vol.20, p.1295, 2001. ,
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study, J Clin Oncol, vol.16, pp.692-701, 1998. ,
Randomized trial comparing bleomycin/ etoposide/ cisplatin with alternating cisplatin/ cyclophosphamide/ doxorubicin and vinblastine/ bleomycin regimens of chemotherapy for patients with intermediate-and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP, J Clin Oncol, vol.26, pp.421-427, 2008. ,
Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial, J Clin Oncol, vol.30, pp.800-805, 2012. ,
« One cycle every 3 or 4 weeks »: is it obsolete? A review of dose-dense chemotherapy in solid neoplasms, Ann Oncol, vol.11, pp.133-149, 2000. ,
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Ann Oncol, 2016. ,
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors, Br J Cancer, vol.86, pp.5904-5910, 1990. ,
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group, Clin Cancer Res, vol.29, pp.2032-2039, 1994. ,
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors, J Clin Oncol, vol.22, pp.3868-3876, 2004. ,
Filgrastim during combination chemotherapy of patients with poorprognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, J Clin Oncol, vol.15, issue.13, pp.716-740, 1998. ,
39-Steyerberg EW, Gerl A, Fosså SD et coll. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer, J Clin Oncol, vol.79, pp.269-274, 1997. ,
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy. Results from an international study group, J Clin Oncol, vol.19, pp.2647-2657, 2001. ,
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors, Eur J Cancer, vol.50, issue.27, p.6549, 2000. ,
José Augusto Rinck, J Clin Oncol, vol.36, 2018. ,
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors, N Engl J Med, vol.357, issue.4, pp.340-348, 2007. ,
Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: longterm results of a prospective randomized trial, J Clin Oncol, vol.30, issue.8, pp.800-805, 2012. ,
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis, J Clin Oncol, vol.28, issue.10, pp.1706-1719, 2010. ,
Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial, Journal of Clinical Oncology, vol.35, issue.6_suppl, pp.4906-4917, 2010. ,
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, issue.4, pp.345-51, 2016. ,
Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT), Germ Cell Tumors: Updates on Epidemiology, vol.35, 2017. ,
An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage, Clin Oncol, vol.36, 2018. ,
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) +/-bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor risk relapsed germ-cell tumors (GCT), Curr Med Chem, vol.15, issue.6, pp.575-583, 2017. ,
Risk stratification for venous thromboembolism in patients with testicular germ cell tumors, vol.12, p.176283, 2017. ,
Klaus-Peter Dieckmann and al. Targeted serum miRNA (TSmiR) test for diagnosis and followup of (testicular) germ cell cancer patients: A proof of principle, /AJCPOE11KEYZCJHT. 59-Ad J.M. Gillis, vol.135, pp.379-388, 2011. ,
Applying radiomics to predict pathology of post chemotherapy retroperitoneal nodal masses in germ cell tumors ,
, J Clin Oncol, vol.35, 2017.
Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test), Oncotarget, vol.8, issue.35, pp.58037-58086, 2017. ,
Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours, European urology, vol.71, issue.2, pp.213-233, 2017. ,
Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors, Andrology, vol.6, issue.4, pp.597-604, 2018. ,
Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, American Society of Preventive Oncology, vol.25, issue.5, pp.773-782, 2016. ,
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study, Testosterone deficiency in testicular cancer survivors -a systematic review and meta-analysis, vol.28, pp.4649-57, 2010. ,
, , vol.4, pp.382-390, 2016.
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study, J Clin Oncol, vol.31, issue.30, pp.3807-3821, 2013. ,
Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients, Clin Cancer Res, vol.24, issue.8, pp.1866-1871, 2018. ,
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study, Cancer Res, vol.76, issue.13, pp.3690-701, 2016. ,
73-Hink Boer. Safety and usefulness of patient-centered shared survivorship care after chemotherapy for testicular cancer, Clin Cancer Res, vol.23, pp.5757-5768, 2017. ,